Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 321

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report

Open access
Chan, Henry Lik-Yuen, Thompson, Alex, Martinot-Peignoux, Michelle, Piratvisuth, Teerha, Cornberg, Markus, Brunetto, Maurizia Rossana, Tillmann, Hans L., Kao, Jia-Horng, Jia, Ji-Dong, Wedemeyer, Heiner, Locarnini, Stephen, Janssen, Harry L.A., Marcellin, Patrick·2011·Journal of Hepatology

Abstract

Quantitative HBsAg had been suggested to be helpful in management of HBV, but assays were cumbersome. The recent availability of commercial quantitative assays has restarted the interest in quantitative serum hepatitis B surface antigen (HBsAg) as a biomarker for prognosis and treatment response in chronic hepatitis B. HBsAg level reflects the transcriptional activity of cccDNA rather than the absolute amount of cccDNA copies. Serum HBsAg level tends to be higher in hepatitis B e antigen (HBeAg)-positive than HBeAg-negative patients. Among patients with a low HBV DNA (<2000IU/ml), HBsAg <1000IU/ml in genotype D HBV infection and HBsAg <100IU/ml in genotype B/C HBV infection is associated with inactive carrier state in HBeAg-negative patients. The HBsAg reduction by nucleos(t)ide analogues (NA) is not as pronounced as by interferon treatment. On peginterferon treatment, sustained responders tend to show greater HBsAg decline than the non-responders. The optimal on-treatment HBsAg cutoff to predict response needs further evaluation in HBeAg-positive patients, but an absence of HBsAg decline together with a <2 log reduction in HBV DNA at week 12 can serve as stopping rule in HBeAg-negative patients with genotype D HBV infection. A rapid serum HBsAg decline during NA therapy may identify patients who will clear HBsAg in the long-term. There are early reports among Asian patients that an HBsAg level of <100IU/ml might predict lower risk of relapse after stopping NA treatment. In clinical practice, serum HBsAg level should be used together with, but not as a substitute for, HBV DNA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2011.06.006

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 321

Metadata

Authors
Chan, H. L.-Y., Thompson, A., Martinot-Peignoux, M., Piratvisuth, T., Cornberg, M., Brunetto, M. R., Tillmann, H. L., Kao, J.-H., Jia, J.-D., Wedemeyer, H., Locarnini, S., Janssen, H. L. A., & Marcellin, P.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2011-11
Volume
55
Issue
5
Pages
1121-1131
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2008643979
Cited by
321
References
42
FWCI
26.80
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report. https://app.cochat.ai/papers/10.1016/j.jhep.2011.06.006
The paper
Chan, H. L.-Y., Thompson, A., Martinot-Peignoux, M., Piratvisuth, T., Cornberg, M., Brunetto, M. R., Tillmann, H. L., Kao, J.-H., Jia, J.-D., Wedemeyer, H., Locarnini, S., Janssen, H. L. A., & Marcellin, P. (2011). Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2011.06.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.